I de første langvarige undersøgelser var der ingen forskel mellem Valdoxan og placebo med hensyn til at forhindre, at symptomerne kom igen under 26 ugers behandling.
In the first of the long-term studies, there was no difference between Valdoxan and placebo in preventing symptoms returning during 26 weeks of treatment.